PL354799A1 - Complex containing ocif and polysaccharide - Google Patents

Complex containing ocif and polysaccharide

Info

Publication number
PL354799A1
PL354799A1 PL02354799A PL35479902A PL354799A1 PL 354799 A1 PL354799 A1 PL 354799A1 PL 02354799 A PL02354799 A PL 02354799A PL 35479902 A PL35479902 A PL 35479902A PL 354799 A1 PL354799 A1 PL 354799A1
Authority
PL
Poland
Prior art keywords
polysaccharide
complex containing
containing ocif
ocif
complex
Prior art date
Application number
PL02354799A
Other languages
English (en)
Inventor
Shinichi Yamamoto
Junichi Okada
Atsushi Kurihara
Taku Numazawa
Junichi Kondo
Eisuke Tsuda
Shinichi Mochizuki
Hirotaka Nishi
Hideki Miyazaki
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of PL354799A1 publication Critical patent/PL354799A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL02354799A 2001-06-29 2002-06-28 Complex containing ocif and polysaccharide PL354799A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001198985 2001-06-29

Publications (1)

Publication Number Publication Date
PL354799A1 true PL354799A1 (en) 2002-12-30

Family

ID=19036337

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02354799A PL354799A1 (en) 2001-06-29 2002-06-28 Complex containing ocif and polysaccharide

Country Status (22)

Country Link
US (3) US20030045456A1 (enExample)
EP (1) EP1270015A3 (enExample)
KR (1) KR20030003124A (enExample)
CN (1) CN1442201A (enExample)
AR (1) AR034716A1 (enExample)
AU (1) AU783126B2 (enExample)
BR (1) BR0202439A (enExample)
CA (1) CA2392383A1 (enExample)
CO (1) CO5390084A1 (enExample)
CZ (1) CZ20022231A3 (enExample)
HK (1) HK1048762A1 (enExample)
HU (1) HUP0202119A2 (enExample)
IL (1) IL150448A0 (enExample)
MX (1) MXPA02006511A (enExample)
NO (1) NO20023144L (enExample)
PA (1) PA8549401A1 (enExample)
PE (1) PE20030254A1 (enExample)
PL (1) PL354799A1 (enExample)
RU (1) RU2232594C2 (enExample)
SG (1) SG98059A1 (enExample)
SK (1) SK9492002A3 (enExample)
ZA (1) ZA200205164B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO2000024416A1 (en) 1998-10-28 2000-05-04 Snow Brand Milk Products Co., Ltd. Remedies for bone metabolic errors
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
EP1482978A1 (en) * 2002-03-01 2004-12-08 Sankyo Company, Limited Pharmaceutical composition comprising osteoclastogenesis inhibitory factor
AU2003240754B2 (en) 2002-04-10 2009-02-26 Merck Serono Sa Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
US7585840B2 (en) * 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
AU2003242265A1 (en) * 2002-06-07 2003-12-22 Sankyo Company, Limited Combined effects of therapeutic or preventive agent composition for bone breakage
RU2323227C2 (ru) * 2003-03-24 2008-04-27 Санкио Компани Лимитед Полимерные модификаторы и фармацевтические композиции
KR100840830B1 (ko) * 2006-09-03 2008-06-23 재단법인서울대학교산학협력재단 고분자 히알루론산을 포함하는 골흡수 저해용 조성물
RU2370271C2 (ru) * 2006-11-22 2009-10-20 Государственное учреждение гематологический научный центр Российской академии медицинских наук (ГУ ГНЦ РАМН) Способ обнаружения комплексов между гепаринами и поликатионами
ITMI20121316A1 (it) * 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
CN115594776B (zh) * 2022-09-19 2024-03-15 山东大学 一种ROS响应性聚合物Mal-PHB-Dextran及细胞背包载药系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US45456A (en) * 1864-12-13 Improved apparatus for carbureting air
US216297A (en) * 1879-06-10 Improvement in ironing-stands
US139325A (en) * 1873-05-27 Improvement in carriage-springs
US181418A (en) * 1876-08-22 Improvement in gas apparatus
US4207A (en) * 1845-09-27 lewis
US31725A (en) * 1861-03-19 Improvement in cultivators
TW318142B (enExample) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
DE69834719D1 (de) * 1997-09-24 2006-07-06 Sankyo Co Methode zur diagnose von abnormalem knochenstoffwechsel
ATE230752T1 (de) * 1998-06-15 2003-01-15 Takeda Chemical Industries Ltd Thienodipyridinderivate, ihre herstellung und verwendung
WO2000024416A1 (en) * 1998-10-28 2000-05-04 Snow Brand Milk Products Co., Ltd. Remedies for bone metabolic errors
KR20010085996A (ko) * 1999-09-03 2001-09-07 스티븐 엠. 오드레 암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
IL155097A0 (en) * 2000-09-28 2003-10-31 Nanocyte Inc Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
EP1482978A1 (en) * 2002-03-01 2004-12-08 Sankyo Company, Limited Pharmaceutical composition comprising osteoclastogenesis inhibitory factor

Also Published As

Publication number Publication date
SG98059A1 (en) 2003-08-20
IL150448A0 (en) 2002-12-01
SK9492002A3 (en) 2003-02-04
CZ20022231A3 (cs) 2003-02-12
NO20023144L (no) 2002-12-30
AU783126B2 (en) 2005-09-29
PA8549401A1 (es) 2003-07-28
HU0202119D0 (enExample) 2002-08-28
BR0202439A (pt) 2003-06-10
CN1442201A (zh) 2003-09-17
ZA200205164B (en) 2003-03-24
US20030045456A1 (en) 2003-03-06
RU2002117385A (ru) 2004-01-27
HK1048762A1 (en) 2003-04-17
US20030139325A1 (en) 2003-07-24
CO5390084A1 (es) 2004-04-30
KR20030003124A (ko) 2003-01-09
RU2232594C2 (ru) 2004-07-20
MXPA02006511A (es) 2004-08-11
CA2392383A1 (en) 2002-12-29
NO20023144D0 (no) 2002-06-28
US20060084595A1 (en) 2006-04-20
HUP0202119A2 (hu) 2003-04-28
PE20030254A1 (es) 2003-03-19
AR034716A1 (es) 2004-03-17
AU5071902A (en) 2003-01-02
EP1270015A3 (en) 2004-02-25
EP1270015A2 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
EP1463742A4 (en) NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
IL161384A0 (en) Bicyclic oxopyridine and oxopyrimidine derivatives
AU2002352903A8 (en) Mesoporous materials and methods
AU2002359126A8 (en) Benzodiazepine derivatives, preparation thereof and use thereof
EP1408978A4 (en) NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
AU2002359123A8 (en) Benzodiazepine derivatives, preparation thereof and use thereof
EP1434772A4 (en) CONNECTIONS AND METHODS
IL154553A0 (en) Urocortin-iii and uses thereof
AU2003296369A8 (en) Imminoamines and preparation thereof
SG98059A1 (en) A complex comprising ocif and polysaccharide
GB0126889D0 (en) Compounds and their uses
AU2002361337A8 (en) Amphoteric polysaccharide, composition and use
EP1392317A4 (en) SUBSTITUTED 1-BENZAZEPINE AND DERIVATIVES THEREOF
AU2002359694A8 (en) Compounds and methods
EP1408985A4 (en) NEW PYRIDOPYRIMIDONE AND ITS USES
GB0201151D0 (en) Ground-connection structure ground-connecting member and ground-connection met d
GB0107628D0 (en) Substances
GB0114533D0 (en) Substances
HUP0401162A3 (en) Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives
PL363290A1 (en) 1k-polyurethane lacquer and use thereof
EP1379240A4 (en) CONNECTIONS AND METHODS
IL161598A0 (en) Use of chitosan materials
GB0115071D0 (en) Substances
EP1367123A4 (en) NEUROTONIN AND ITS USE
GB0200843D0 (en) Benzodioxinopyrroles their preparation and use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)